Black Rock Inc. Phase Bio Pharmaceuticals Inc Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.64 - $1.35 $11,930 - $25,165	-18,641 Reduced 2.72%	665,563 $116,000
Q2 2022 Aug 12, 2022	BUY	$0.52 - $1.59 $1,410 - $4,313	2,713 Added 0.4%	684,204 $411,000
Q1 2022 May 12, 2022	SELL	$0.97 - $2.66 $3,788 - $10,389	-3,906 Reduced 0.57%	681,491 $899,000
Q4 2021 Feb 10, 2022	BUY	$1.9 - $4.05 $315,472 - $672,453	166,038 Added 31.97%	685,397 $1.79 Million
Q3 2021 Nov 09, 2021	BUY	$2.72 - $3.85 $87,951 - $124,489	32,335 Added 6.64%	519,359 $1.62 Million
Q2 2021 Aug 11, 2021	BUY	$2.7 - $3.98 $1.31 Million - $1.94 Million	487,024 New	487,024 $1.81 Million

Ticker PHAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,858,100
Description
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or li...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.